Study Examines New Drug for Type 2 Diabetes

Understanding Type 2 Diabetes

A recent study published in *Science Translational Medicine* explored the clinical efficacy and safety of a novel diabetes medication. Type 2 diabetes is a condition where the body struggles to regulate blood sugar levels. Typically, the pancreas releases insulin, enabling the body to convert sugars into energy. In individuals with type 2 diabetes, insulin response is impaired, leading to elevated blood sugar levels. This chronic disease affects millions globally and heightens the risk of serious health issues, including kidney, liver, and cardiovascular diseases.

Current Treatment Challenges

Insulin therapy is often prescribed to manage diabetes; however, it can lead to side effects such as hypoglycemia and weight gain. With the increasing prevalence of type 2 diabetes, researchers are actively investigating new pharmaceutical options.

Targeting Glucokinase for Improved Outcomes

Some healthcare professionals have reported success with treatment strategies that focus on glucokinase, a protein critical to sugar processing in cells. Drugs that activate glucokinase tend to enhance sugar metabolism, resulting in lower blood sugar levels. Importantly, the role of glucokinase varies between the pancreas and liver.

Clinical Trials of TTP399

Activation of Glucokinase in the Liver

Scientists propose that selectively activating glucokinase in the liver can facilitate glucose uptake without impacting insulin production by the pancreas, thereby avoiding low blood sugar. A research team from the United States developed a new diabetes medication that specifically activates glucokinase in the liver. Their clinical trial involving human patients with type 2 diabetes was recently published in *Science Translational Medicine*.

Discovery and Preclinical Testing

The researchers identified the drug TTP399 by screening various compounds in liver and pancreatic cells from human and animal sources. TTP399 was effective in activating glucokinase in liver cells without influencing insulin secretion from pancreatic cells. Subsequent tests in animal models demonstrated that TTP399 did not affect healthy rats but successfully helped diabetic rats regulate blood sugar levels and reduce weight gain while maintaining normal insulin levels.

Details of the Clinical Trial

The clinical trial recruited 190 patients with type 2 diabetes who were already on metformin, a medication that enhances insulin sensitivity. Participants received either a low dose of TTP399, a high dose, an alternative drug, or a placebo.

Results and Implications

Positive Outcomes from Higher Doses

Patients receiving the higher dose of TTP399 exhibited sustained improvements in blood sugar control and a favorable blood lipid profile. Notably, participants weighing 100 kg or more experienced weight loss compared to those on the placebo. The drug demonstrated a strong safety profile, with no severe side effects or instances of hypoglycemia reported.

Conclusions and Future Research

The study confirmed that TTP399 does not induce low blood sugar, a common issue with other glucokinase-activating drugs. The authors also highlighted the positive impact of TTP399 on blood sugar control indicators. Nevertheless, further trials are necessary to validate the long-term safety and efficacy of this medication. The research team suggests that TTP399 may offer a more therapeutically viable option than similar drugs that affect insulin production. This study underscores the importance of drugs that selectively target specific areas of the body to minimize unwanted side effects.

Reference

Vella A, Freeman JL, Dunn I, Keller K, Buse JB, Valcarce C. Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. *Science Translational Medicine*. 2019 Jan 16;11(475):eaau3441.